(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 72.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Insmed's revenue in 2025 is $381,030,000.On average, 7 Wall Street analysts forecast INSM's revenue for 2025 to be $85,620,229,202, with the lowest INSM revenue forecast at $81,676,557,241, and the highest INSM revenue forecast at $88,692,548,555. On average, 7 Wall Street analysts forecast INSM's revenue for 2026 to be $191,425,093,850, with the lowest INSM revenue forecast at $164,398,591,900, and the highest INSM revenue forecast at $213,290,143,001.
In 2027, INSM is forecast to generate $379,074,812,105 in revenue, with the lowest revenue forecast at $316,266,025,897 and the highest revenue forecast at $430,674,951,129.